Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): An observational study in a single institution

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 633-641

  Schallier, D ^a   Decoster, L ^a   Braeckman, J ^a   Fontaine, C ^a   Degreve J ^a  

^a Oncologisch Centrum UZ   (Belgium)

Author keywords

Castration resistant; Chemotherapy; Docetaxel; Metastatic; Methylprednisolone; Prostate cancer

Indexed keywords

ABIRATERONE; DOCETAXEL; ESTRAMUSTINE; IPILIMUMAB; METHYLPREDNISOLONE; MITOXANTRONE; PACLITAXEL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DRY SKIN; ESOPHAGITIS; FLUID RETENTION; HAIR LOSS; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84856942153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics 2009. CA Cancer J Clin 59: 225-249, 2009.
2. American Cancer Society. Global cancer facts and figures 2007. http://www.cancer.org/acs/groups/contenty@nho/documents/document/ globalfactsandfigures2007rev2p.pdf(accessed Sept 14, 2010).
3. Eisenberger MA, Simon R, O'Dwyer PJ and Friedman HA: A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827-841, 1985. (Pubitemid 15062911)
4. Tannock IF, de Wit R, Berry WR, Hoti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal M and Eisenberger M for the TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
5. Petrylak DP, Tangen CM, Hussein MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
6. Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin M, Burch A, Hussein MH and Crawford ED: Quality of life and pain in advanced prostate cancer: results of a Southwest Group randomized trial comparing docetaxel and estramustine to mitoxantone and prednisone. J Clin Oncol 24: 2828-2835, 2006. (Pubitemid 46630582)
7. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussein MH, Wilding G, Gross M, Hutcheon D and Small EJ: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110: 556-563, 2007. (Pubitemid 47106144)
8. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM and Murphy KC: Chemotherapy with mitoxantone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996. (Pubitemid 26185452)
9. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S and Sartor AO, for the TROPIC Investigators: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376: 1147-1154, 2010.
10. Danila D, Rathcompf D, Morris M, Slovin SF, Schwartz LH, Farmer K, Anand A, Haqq C, Fleisher M and Scher HI: Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. J Clin Oncol 26(suppl): 254s (abstract 5019), 2008.
11. de Bono JS, Logothetis C, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman O, Saad F, Staffuurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth J, Ryan CJ, Sternberg C, Ellard S, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM and Scher HI for the COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005, 2011.
12. Mountzios I, Bournakis E, Efsthathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A and Dimopoulos MA: Intermittent docetaxel chemotherapy in patients with castration-resistant prostate cancer. Urology 77(3): 682-687, 2011.
13. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A and Fizazi K: The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46: 1770-1772, 2010.
14. National Cancer Institute Cancer Therapy Evaluation Program: Common Terminology Criteria for AdverseEvents v3.0. (CTCAE).http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3pdf.
15. Kirkwood BR: Essentials of Medical Statistics. Blackwell Science, pp. 43-45, 2001.
16. Simon R: Confidence intervals for reporting results of clinical trials. Ann Intern Med 53: 429-435, 1986.
17. Kaplan EL and Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 487-581, 1958.
18. Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF and Sonpavde G: Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 61: 363-369, 2011.